The short version of method validation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
Regulatory and pharmacopeial texts shape how HPLC testing is performed and documented. The International Council for Harmonisation provides validation guidance, while pharmacopeias publish general chromatography chapters and monographs for specific materials. Accreditation standards such as ISO/IEC 17025 address laboratory competence and traceability. Inspectors may review instrument qualification, analyst training, reference material control, and electronic records. Open questions include how best to validate methods for new complex products and how to handle automated data processing. Laboratories generally resolve these issues through risk assessment, method lifecycle management, and documented scientific justification.
Separation performance depends on particle size, pore size, column length, and the chemistry of the stationary phase. Smaller particles generally improve efficiency but require higher pressure and suitable instrumentation. The mobile phase often contains buffers and organic solvents that influence retention and selectivity. Testing labs select conditions based on the analytes, sample matrix, and required sensitivity. Method development frequently involves screening several columns and solvent mixtures before a final set of conditions is chosen.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample by passing them through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in how analytes partition between the mobile phase and the stationary phase cause them to exit the column at different times. Detection then records a signal proportional to the amount of each separated substance. The resulting chromatogram provides retention times and peak areas for identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Primary guidance | ICH Q2(R2) | Analytical procedure validation |
| Compendial chapter | USP <621> | Chromatography general chapter |
| Validation parameter | Accuracy | Closeness to accepted true value |
| System suitability check | Peak resolution | Ensures separation between adjacent peaks |
| Data record | Audit trail | Supports data integrity and traceability |
Routine quality control uses system suitability, blank injections, check standards, and control samples to detect drift or contamination. System suitability criteria may specify minimum resolution, maximum tailing factor, and a permitted range for repeated injections. Blank injections reveal carryover or solvent contamination, while check standards confirm calibration accuracy over a batch. Control samples with known analyte levels can show whether results remain within statistical limits. When a control result falls outside limits, the analyst investigates the cause and may invalidate affected results before repeating the batch.
Documentation and traceability are central to regulated HPLC testing. Records typically include instrument logs, column history, mobile-phase preparation, sample preparation, injection sequences, raw chromatograms, and audit trails. Electronic systems may require user access controls, time-stamped changes, and backup procedures. Training records show that analysts are qualified for assigned methods. Audits and inspections check whether written procedures match actual practice and whether deviations are documented. These controls support reproducibility and allow results to be reconstructed if questions arise later.
CMS determined that this would not be practical and instead is working on publishing a brochure that will be distributed by surveyors to labs, published on the CMS CLIA Web site, and distributed at lab professional meetings. Few labs were the subject of a complaint each year from 2002 through 2004—significantly less than one complaint per lab per year. Concerns that labs can easily identify the lab workers who file complaints and lab workers' lack of familiarity with how to file a complaint may explain why so few laboratory workers report problems. Complaints are an important tool in detecting quality problems between lab surveys. For example, complaints about testing at a hospital lab were crucial because information had been concealed, complicating the detection of quality problems during the lab's surveys. As a result of a complaint, surveyors were able to substantiate inadequate calibration of testing equipment that could adversely affect patient care. Several of the AOs, such as CAP, require laboratories to post the complaint contact signs, but only in employee areas.
Carbodiimides such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC) are frequently used for amide bond formation. The reaction proceeds via the formation of a highly reactive O-acylisourea. This reactive intermediate is attacked by the peptide N-terminal amine, forming a peptide bond. Formation of the O-acylisourea proceeds fastest in non-polar solvents such as dichloromethane. DIC is particularly useful for SPPS since as a liquid it is easily dispensed, and the urea byproduct is easily washed away. Conversely, the related carbodiimide 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is often used for solution-phase peptide couplings as its urea byproduct can be removed by washing during aqueous work-up.
However, it is also in contrast to higher doses of doxepin (50 to 300 mg/day), which have been found to significantly reduce latency to sleep onset. A positive dose–response relationship on sleep measures was observed for doses of doxepin between 1 and 6 mg in clinical studies, whereas the incidence of adverse effects remained constant across this dose range in both young and older adults. However, the incidence of adverse effects appeared to increase with longer treatment duration. A dose of doxepin as low as 1 mg/day was found to significantly improve most of the assessed sleep measures, but unlike the 3 and 6 mg/day doses, was not able to improve wake time during sleep. This, along with greater effect sizes with the higher doses, was likely the basis for the approval of the 3 and 6 mg doses of doxepin for insomnia and not the 1 mg dose. At very low doses, doxepin has not shown discontinuation or withdrawal effects nor rebound insomnia. Sustained effectiveness without apparent tolerance was demonstrated in clinical studies of up to 12 weeks duration. This appears to be in contrast to over-the-counter antihistamines like diphenhydramine and doxylamine and all other first-generation antihistamines, which are associated with rapid development of tolerance and dependence (by day 3 or 4 of continuous dosing) and loss of hypnotic effectiveness. It is for this reason that, unlike doxepin, they are not recommended for the chronic management of insomnia and are advised for only short-term treatment (i.e., 1 week).
==== Health care ==== Duterte vowed to improve the health care system, certifying the Universal Healthcare Bill as an urgent measure as early as July 2018. In February 2019, he signed the Universal Health Care Act, which automatically enrolls all Filipinos under the government's health insurance program. He also enacted the National Integrated Cancer Control Act which establishes a "national integrated" program to control and prevent cancer by making treatment more accessible and affordable, and the Philippine Mental Health Law, which provides free mental health services down to the barangay level while requiring hospitals to provide psychiatric, psychosocial and neurologic services. In December 2019, Duterte signed a law institutionalizing Malasakit Centers in all hospitals run by the Department of Health, allowing indigent patients to efficiently access financial medical assistance from various government agencies. Duterte ordered the full implementation of the Reproductive Health Law, banned smoking in public places nationwide, and set a price cap on select medicines.
Generative AI systems have been used in mathematics and computer science to generate candidate computer programs, proofs, constructions, or algorithms. In 2023, Google DeepMind introduced FunSearch, a method for creating computer programs that solve mathematical and algorithmic problems. FunSearch was used to discover new mathematical constructions in the cap set problem and the bin packing problem. In 2023, Google DeepMind introduced AlphaDev, which was used to discover small sorting algorithms that outperformed previously known human benchmarks and have been integrated into the LLVM standard C++ sorting library. In 2025, Google DeepMind introduced AlphaEvolve, an AI system for general-purpose algorithm discovery and optimization. AlphaEvolve uses LLMs to propose code changes, automated evaluators to assess each candidate, and an evolutionary process to iteratively improve algorithms. In 2026, in response to the increasing use of generative AI in mathematical discovery, a group of mathematicians issued the Leiden Declaration on Artificial Intelligence and Mathematics, which recommends disclosing the use of AI in research papers, ensuring that AI-assisted papers are peer-reviewed, and providing legal resources and public funding so that academia and for-profit companies can compete on equal terms.
Sources: en.wikipedia.org
The most common fault associated with malolactic fermentation is its occurrence when it is not desired. This could be for a wine that is meant to be acidic and fruity (such as Riesling) or it could be a wine that was previously thought to have gone through MLF and bottled only to have malolactic fermentation commence in the bottle. The outcome of this "in-bottle" fermentation is often gassy, hazy wine that can be unpalatable to consumers. Improvement in sanitation and control of lactic acid bacteria in the winery can limit the occurrence of these faults. For early Vinho Verde producers, the slight effervesce that came from in-bottle malolactic fermentation was considered a distinguishing trait that consumers enjoyed in the wine. However, wineries had to market the wine in opaque bottles to mask the turbidity and sediment that the "in-bottle MLF" produced. Today, most Vinho Verde producers no longer follow this practice and instead complete malolactic fermentation prior to bottle with the slight sparkle being added by artificial carbonation. While not necessarily a fault, malolactic fermentation does have the potential of making a wine "protein unstable" due to the resulting change in pH which affects the solubility of proteins in wine. For this reason, protein fining and heat stability tests on wine usually take place after malolactic fermentation has run to completion.
== Production process == Stock cubes are made by mixing already-dry ingredients into a paste, including salt, fat, (meat/bone/vegetable) extract, etc. The ingredients are usually mixed in a container (batch mixing), left to mature, and then shaped into the cube form. Alternatively, they can be mixed directly into an extruder. The "extract" portion needs to be separately produced from the meat, bone, or whatever food is intended to be used in the reconstituted boullion (see meat extract). This is achieved by large-scale cooking similar to what is used to make pre-packaged broth, followed by an evaporation process to condense the product.
However, for such applications actinides are less suitable than lighter radioisotopes as the critical mass is orders of magnitude below the mass needed to produce such amounts of power. As Sr-90, Cs-137 and other lighter radionuclides cannot maintain a nuclear chain reaction under any circumstances, RTGs of arbitrary size and power could be assembled from them if enough material can be produced. In general, however, potential applications for such large-scale RTGs are more the domain of small modular reactors, microreactors or non-nuclear power sources.
== Clinical significance == Insufficient secretion of vasopressin underlies diabetes insipidus, a condition in which the body loses the capacity to concentrate urine. Affected individuals excrete as much as 20 liters of dilute urine per day. Oversecretion of vasopressin causes the syndrome of inappropriate antidiuretic hormone (SIADH).
Sources: en.wikipedia.org
=== Insulin resistance === Isoleucine, like other branched-chain amino acids, is associated with insulin resistance: higher levels of isoleucine are observed in the blood of diabetic mice, rats, and humans. In diet-induced obese and insulin resistant mice, a diet with decreased levels of isoleucine (with or without the other branched-chain amino acids) results in reduced adiposity and improved insulin sensitivity. Reduced dietary levels of isoleucine are required for the beneficial metabolic effects of a low protein diet. In humans, a protein restricted diet lowers blood levels of isoleucine and decreases fasting blood glucose levels. Mice fed a low isoleucine diet are leaner, live longer, and are less frail. In humans, higher dietary levels of isoleucine are associated with greater body mass index.
Aminoacylation is the process of adding an aminoacyl group to a compound. It covalently links an amino acid to the CCA 3′ end of a tRNA molecule. Each tRNA is aminoacylated (or charged) with a specific amino acid by an aminoacyl tRNA synthetase. There is normally a single aminoacyl tRNA synthetase for each amino acid, despite the fact that there can be more than one tRNA, and more than one anticodon for an amino acid. Recognition of the appropriate tRNA by the synthetases is not mediated solely by the anticodon, and the acceptor stem often plays a prominent role. Reaction:
Pappalysin-1, also known as pregnancy-associated plasma protein A, and insulin-like growth factor binding protein-4 protease is a protein encoded by the PAPPA gene in humans. PAPPA is a secreted protease whose main substrate is insulin-like growth factor binding proteins. Pappalysin-1 is also used in screening tests for Down syndrome.
Sources: en.wikipedia.org
System suitability is a set of checks performed before and during an HPLC run to confirm that the instrument and method are working as expected. It may include retention time repeatability, resolution between peaks, peak symmetry, and signal intensity. Failing suitability criteria usually invalidates the run.
An HPLC method is typically validated before its routine use and revalidated in part when significant changes affect the method. Regulators do not set a universal calendar interval. The need for revalidation depends on the change, its risk, and the applicable guidance.
Validation establishes that a method is suitable for its intended purpose, often through a planned study. Verification confirms that a laboratory can reproduce a previously validated or compendial method under its own conditions. Verification is usually narrower than full validation.
HPLC separates and detects individual compounds in a liquid sample, producing peaks at characteristic retention times. Peak area or height can be used to estimate concentration when calibrated with known standards. It does not identify unknown compounds with certainty unless additional detectors or reference materials are used.